Last reviewed: June 12, 2026
Last updated: June 12, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
The FDA has raised questions about certain 503B outsourcing facilities producing semaglutide in bulk, but 503A compounding pharmacies—which operate under different regulations—continue to manufacture semaglutide for individual patient prescriptions. PlexusDx partners exclusively with licensed 503A compounding pharmacies to deliver consistent, quality-tested compounded semaglutide injection starting at $149 per month.
The Difference Between 503A and 503B Compounding Pharmacies
Compounding pharmacies fall into two categories under federal law: 503A facilities operate within individual pharmacy locations and compound medications for specific patients on prescription, while 503B outsourcing facilities produce larger quantities of medications for distribution to multiple healthcare providers. The FDA's recent focus on semaglutide quality has primarily targeted 503B bulk operations, not traditional 503A compounding. PlexusDx exclusively uses 503A licensed compounding pharmacies, which maintain stricter patient-specific oversight and quality controls.
503A pharmacies operate under state board of pharmacy regulation and FDA oversight, but they are not required to undergo the same pre-approval inspections as 503B facilities. This distinction matters because 503A operations are designed to serve individual patient needs with customized compounding, whereas 503B facilities produce standardized batches for broader distribution. The regulatory scrutiny on semaglutide has not extended to traditional 503A compounding, making this model a stable foundation for ongoing medication access.
Why Compounded Semaglutide Remains a Viable Treatment Option
Brand-name semaglutide medications like Ozempic and Wegovy remain in limited supply due to global demand, with some patients experiencing months-long wait times. Compounded semaglutide offers an alternative pathway to GLP-1 therapy by using the same active pharmaceutical ingredient manufactured through licensed pharmacies. The FDA does not consider 503A compounding of semaglutide unlawful when prescribed by a licensed healthcare provider, provided the pharmacy operates in compliance with state and federal guidelines.
Clinical outcomes with compounded semaglutide mirror those of brand medications because the active ingredient is identical. Patients using compounded semaglutide achieve similar weight loss results and metabolic improvements as those using branded formulations. PlexusDx patients gain immediate access without insurance requirements or membership fees, making compounded therapy both medically sound and financially accessible across all 50 states.
How PlexusDx Ensures Quality and Compliance in Compounded Medications
PlexusDx partners with licensed 503A compounding pharmacies that meet rigorous quality standards, including sterile compounding techniques, ingredient verification, and batch testing. Each medication is prepared according to the patient's prescription and undergoes quality assurance checks before dispensing. PlexusDx does not work with 503B outsourcing facilities, eliminating exposure to the regulatory concerns the FDA has flagged regarding bulk semaglutide production.
The company's commitment to transparency means patients understand exactly where their medication comes from and how it is prepared. PlexusDx provides documentation confirming 503A pharmacy status and maintains relationships with facilities that voluntarily exceed minimum compliance requirements. This approach protects patient safety while preserving access to compounded GLP-1 therapy regardless of future regulatory developments affecting the broader compounding landscape.
Looking Ahead: The Stability of Compounded GLP-1 Therapy
Regulatory scrutiny of semaglutide compounding is likely to continue, but the focus remains on protecting patients from low-quality or dangerous operations. Licensed 503A pharmacies that operate transparently and maintain proper quality controls face minimal disruption risk. PlexusDx's exclusive partnership with compliant 503A facilities positions patients for long-term medication access, with compounded semaglutide injection starting at $149 per month and remaining available across all U.S. states.
Future regulatory changes may affect how compounding operates, but they will not eliminate it. The FDA recognizes the medical necessity of compounding for patients with unmet needs, including those unable to access brand-name GLP-1 medications. PlexusDx continues to monitor regulatory developments and maintains partnerships with facilities best positioned to weather any industry-wide changes. Patients beginning compounded semaglutide therapy through PlexusDx can do so with confidence in both the medication's quality and its long-term availability.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is compounded semaglutide legal and FDA-approved?
Compounded semaglutide is legal when prescribed by a licensed healthcare provider and prepared by a licensed 503A compounding pharmacy. The FDA does not approve individual compounded prescriptions but does permit compounding under federal and state law. PlexusDx uses only licensed 503A pharmacies to ensure compliance and quality.
What happens if the FDA bans compounded semaglutide?
The FDA has not proposed banning 503A compounding of semaglutide; regulatory action has focused on 503B bulk facilities with quality control problems. Licensed 503A operations face minimal disruption risk due to their patient-specific, transparent model. PlexusDx's exclusive use of 503A pharmacies protects against future supply disruptions.
How much does compounded semaglutide cost through PlexusDx?
PlexusDx compounded semaglutide injection starts at $149 per month with no insurance required, no membership fees, and HSA/FSA eligibility. Your dose may need to go up. Your price won't. The flat monthly rate remains consistent regardless of dose adjustments.
Is compounded semaglutide as effective as brand-name Ozempic or Wegovy?
Compounded semaglutide contains the same active ingredient as brand formulations and produces equivalent weight loss and metabolic outcomes in clinical practice. Efficacy depends on proper dosing and individual response, not whether the medication is branded or compounded. PlexusDx works with prescribing providers to optimize dosing based on patient needs.
Can genetic testing help me choose between compounded semaglutide and other GLP-1 options?
PlexusDx's Precision Peptide Genetic Test analyzes 14 pathways and 150+ genetic insights, including GLP1R rs6923761 and GIPR rs1800437 variants that influence GLP-1 medication response. The $99 test (available after month one) helps providers personalize therapy selection and dosing, ensuring you receive the most effective GLP-1 option for your genetic profile.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Drinking Alcohol While Taking Ozempic: Navigating Your Weight Loss Journey
Can You Drink When Taking Ozempic for Weight Loss?